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Abstract
Background: Stroke, the leading neurologic cause of death and disability, has a substantial genetic component. We
previously conducted a genome-wide association study (GWAS) in four prospective studies from the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) consortium and demonstrated that sequence variants near the NINJ2
gene are associated with incident ischemic stroke. Here, we sought to fine-map functional variants in the region and
evaluate the contribution of rare variants to ischemic stroke risk.
Methods and Results: We sequenced 196 kb around NINJ2 on chromosome 12p13 among 3,986 European ancestry
participants, including 475 ischemic stroke cases, from the Atherosclerosis Risk in Communities Study, Cardiovascular Health
Study, and Framingham Heart Study. Meta-analyses of single-variant tests for 425 common variants (minor allele frequency
[MAF] $ 1%) confirmed the original GWAS results and identified an independent intronic variant, rs34166160 (MAF = 0.012),
most significantly associated with incident ischemic stroke (HR= 1.80, p = 0.0003). Aggregating 278 putatively-functional
variants with MAF# 1% using count statistics, we observed a nominally statistically significant association, with the burden
of rare NINJ2 variants contributing to decreased ischemic stroke incidence (HR= 0.81; p = 0.026).
Conclusion: Common and rare variants in the NINJ2 region were nominally associated with incident ischemic stroke among
a subset of CHARGE participants. Allelic heterogeneity at this locus, caused by multiple rare, low frequency, and common
variants with disparate effects on risk, may explain the difficulties in replicating the original GWAS results. Additional studies
that take into account the complex allelic architecture at this locus are needed to confirm these findings.
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Introduction
Stroke is the leading neurologic cause of death and disability.[1]
Twin and familial aggregation studies suggest that the risk of stroke
has a substantial genetic component[2–4], but few genes
underlying this risk in the general population have been
elucidated. Previously, we conducted a genome-wide association
study in four prospective cohorts comprising the Cohorts for Heart
and Aging in Genomic Epidemiology (CHARGE) consortium that
identified and replicated associations of two common single
nucleotide polymorphisms (SNPs) with risk of incident ischemic
stroke among 19,602 individuals of European ancestry, who
suffered 1164 incident ischemic strokes over an average follow-up
of 11 years.[5] Both SNPs were in close proximity to NINJ2, which
encodes ninjurin2, an adhesion molecule expressed in glia that
plays a role in neurite growth, ischemic tolerance, and inflamma-
tion response, and that may influence how the brain responds to
an ischemic insult.[6] These two SNPs were in linkage disequi-
librium (LD) with each other (r2 = 0.73 based on HapMap CEU
data, NCBI build 36) as well as with other variants in the 59
untranslated region of NINJ2. We observed even stronger
associations when the analyses were restricted to ischemic strokes
of atherothrombotic origin.
Subsequent reports have been conflicting about the association
of the NINJ2 SNPs with ischemic stroke. Independent attempts to
replicate these findings in large case-control samples were
unsuccessful [7–9], although other smaller studies have observed
associations of these variants with risk.[10–13]
In order to clarify the role of sequence variation in this region in
the etiology of incident ischemic stroke, we sequenced a 196 kb
region of chromosome 12 that contains the NINJ2 gene, part of the
WNK1 gene, and their intergenic sequence, among a subsample
from 3 cohorts of the CHARGE consortium. Our aim was to
detail the landscape of common and rare variation in this region
and to identify novel variants underlying associations with
ischemic stroke at this locus.
Methods
Participating Studies and Study Design
Our analyses were performed as part of the Cohorts for Heart
and Aging Research in Genomic Epidemiology Targeted
Sequencing Study (CHARGE-S), which aimed at following up
GWAS signals for a wide array of cardiovascular related traits to
identify functional variants and to evaluate the contribution of rare
variants. The CHARGE consortium is a collaborative program of
prospective population-based cohorts seeking to identify suscepti-
bility genes for cardiovascular, lung, and blood diseases and their
risk factors.[14]
This project focused on a subset of 3,986 participants of
European ancestry from the Atherosclerosis Risk in Communities
Study (ARIC), the Cardiovascular Health Study (CHS), and the
Framingham Heart Study (FHS), and included 229 individuals
selected based on their stroke phenotype and representing a
targeted subsample of individuals from the genome-wide associ-
ation study discovery effort. Information about the 3 cohorts’ study
design and recruitment is included in File S1.
In each of the 3 cohorts, participants with available DNA and
consent who experienced an incident ischemic stroke after age 65
were eligible for selection. This sample was enriched for
participants in whom incident stroke was of atherothrombotic
origin, preferentially selecting those with the earliest onset, with
equal numbers of men and women, and in numbers proportional
to the sample size of the participating cohorts. In our epidemi-
ological samples, ‘atherothrombotic brain infarction’ is defined as
a clinical ischemic stroke consistent with occlusion of an extra-or
intracranial artery, that is, a clinical ischemic stroke not suspected
to be either of cardioembolic origin or due to an identified non-
atherothrombotic etiology (such as arterial dissection). This
category includes the subtypes of large artery atherosclerosis,
small-artery occlusion (lacunes) and undetermined origin. The
atherothrombotic stroke phenotype was selected because it yielded
the strongest association with NINJ2 variants in our previous
GWAS meta-analysis.[5] Seventy-one atherothrombotic stroke
cases were sequenced in ARIC; 105 in CHS and 53 in FHS.
The remaining participants in this study were selected as part of
a Cohort Random Sample or for extreme values of other
NINJ2 Sequencing in Ischemic Stroke
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Reinvestment Act of 2009 (ARRA) (5RC2HL102419). Data for ‘‘Building on GWAS for NHLBI-diseases: the U.S. CHARGE Consortium’’ was provided by Eric Boerwinkle on
cardiovascular phenotypes. Among these, 246 also experienced an
incident ischemic stroke during study follow-up.
Ethics Statement. All subjects provided written and in-
formed consent to participate in genetic studies, and all study sites
received approval to conduct this research from their local
respective Institutional Review Boards (IRB), including the
Committee for the Protection of Human Subjects at the University
of Texas Health Science Center at Houston, University of
Mississippi Medical Center IRB (ARIC – Jackson Field Center),
Wake Forest University Health Sciences IRB (ARIC – Forsyth
County Field Center), University of Minnesota IRB (ARIC –
Minnesota Field Center), Johns Hopkins University IRB (ARIC
and CHS – Washington County Field Centers), Wake Forest
University Health Sciences IRB (CHS – Forsyth County Field
Center), University of California, Davis IRB (CHS – Sacramento
County Field Center), University of Pittsburgh IRB (CHS –
Pittsburgh Field Center), and Boston University IRB (FHS).
Stroke phenotypes
Stroke was defined as a focal neurologic deficit of presumed
vascular cause with a sudden onset and lasting for at least 24 hours
or until death if the participant died less than 24 hours after the
onset of symptoms. Details of stroke surveillance and diagnostic
criteria for stroke and stroke types in the three studies have been
published [15–21] and are summarized in File S1. Strokes were
classified as ischemic, hemorrhagic, or unknown type on the basis
of clinical and imaging criteria. For this study, we considered only
ischemic strokes.
Sequencing
The methods of the CHARGE Targeted Sequencing Study
have been previously described (Lin H, Wang M, Brody JA, Bis
JC, Dupuis J, Lumley T, et al., accepted to Circ Cardiovasc Genet).
Briefly, the Study sequenced a total of 77 target regions that
harbor genetic variants associated with 14 phenotypes implicated
by GWAS within the CHARGE consortium. In particular, the
Neurology working group selected the NINJ2 gene region from the
University of California at Santa Cruz (UCSC) Genome Browser,
with the aim of capturing all sequence variation upstream and
downstream of the gene.
Approximately 2 Mb of target regions were captured by a
customized NimbleGen Capture array and then sequenced using
the ABI SOLiD V4.0 platform. The raw short reads were aligned
to the reference human genome (NCBI Genome Build 36, hg18)
by BFAST.[22] SAMtools[23] was used to pile up aligned reads
and call variants with quality filters. The resulting data were then
subjected to quality control (QC) procedures, including variant-
level and sample-level QC. Detailed QC methods are described in
the accompanying CHARGE Targeted Sequencing Study Design
manuscript. Variants were categorized as known or novel by
comparison with the dbSNP database and the 1000 Genomes
Project. Functional annotations were produced using a combina-
tion of ANNOVAR,[24] dbNSFP,[25] and custom internal tools.
Statistical analysis
Each study independently implemented the predefined analysis
plan described next and results from the 3 studies were combined
by meta-analytic techniques.
In each study, Cox proportional hazard models were used to
assess association of variants with incident ischemic stroke.
Participants with prevalent stroke were excluded from the analysis.
Participants who experienced a stroke not classified as ‘‘ischemic’’
were censored at time of alternative type of stroke. Although
atherothrombotic strokes were enriched in the subset of stroke
cases selected for sequencing, our primary analyses included all
incident ischemic strokes, including those sequenced as part of the
Cohort Random Sample or selected for other Phenotype Groups,
to maximize sample size since we did not have adequate power to
perform analyses restricted only to atherothrombotic strokes.
Models were adjusted for age and sex. Additional adjustments
included study site for CHS and ARIC, and familial structure for
FHS.
For each variant with a minor allele frequency (MAF) $ 1% in
the combined population, each study fitted additive genetic
models, regressing trait on genotype dosage (0 to 2 copies of the
variant allele). Meta-analyses of standard regression coefficients
[26] were used to determine significance, but we repeated these
analyses weighted by each participant’s sampling probability to
obtain valid estimates of effect size. (Lumley T, Dupuis J, Rice
KM, Barbalic M, Bis JC, Cupples LA, et al. http://stattech.
wordpress.fos.auckland.ac.nz/files/2012/05/design-paper.pdf).
Our primary hypothesis focused on descriptive analyses of
sequence variants in the NINJ2 regions. Given the prior evidence
for this region in this sample, we used a p-value threshold
corresponding to one expected false discovery among the total
number of SNPs tested to identify variants of potential interest
(p = 1/425= 0.002).
The primary analysis for rare variants was to aggregate variants
of MAF ,1% and with predicted functional changes on encoded
proteins[24] or gene regulation, into a T1 count statistic, defined
as the sum of the number of variant sites in the target at which a
person has at least one rare allele with MAF ,1%. We annotated
variants using a heuristic scoring system implemented in
RegulomeDB, which represents the confidence that a variant
has a functional impact on gene regulation.[27] The burden of
variants of MAF ,1% with predicted functional impact on
proteins (amino-acid change) and on gene regulation (Regulo-
meDB score #3) was evaluated for association with incident
ischemic stroke.
To explore the possibility that rare variants within a gene did
not have the same direction or magnitude of association, we also
implemented the Sequence Kernel Association Test (SKAT)[28],
which approximates the score test that would be obtained fitting a
model that includes all the variants, using customized R scripts for
meta-analyses. (Lumley T, Brody J, Dupuis J, Cupples LA http://
stattech.wordpress.fos.auckland.ac.nz/files/2012/11/skat-meta-paper.
pdf).
Results
Our analysis included 3,986 participants who successfully
completed targeted sequencing. Characteristics of these partici-
pants from the 3 participating cohorts are shown in Table 1 and in
the Supplemental Material (Table S1 in File S1). In general,
participants selected for sequencing had their stroke event early in
the follow-up period, except in ARIC where events were uniformly
distributed across the follow-up period. Age at stroke onset was
similar across the 3 cohorts.
Resequencing of the NINJ2 region on chromosome 12p13
between base pairs 543,643 and 740,130 (NCBI Build 36, 2006)
on 3,986 individuals identified 4,001 variants, including 3,077 not
previously identified in the 1000 Genomes Project (Table 2).
Twenty-eight were coding variants. Across all SNPs in the NINJ2
target region, the average 2.5% coverage percentile was 37.8X
and the 97.5% percentile was 45.4X, indicating excellent sequence
coverage of the NINJ2 gene region.
Our primary analyses of the NINJ2 locus focused on 425
individual common variants and aggregated tests of 278 rare
NINJ2 Sequencing in Ischemic Stroke
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putatively-functional variants. Genomic annotation for these
variants is shown in Table S2 in File S1.
Common Variants Results
Figure 1 displays a regional association plot showing the results
for the meta-analysis of common variants. We confirmed the
association of the previously-reported sentinel GWAS SNP
rs11833579 (Hazard Ratio (HR)= 1.39, p = 0.0005) with incident
ischemic stroke in this smaller targeted sample. The second
GWAS SNP, rs12425791, was only borderline significant based on
our threshold of one expected false discovery (HR=1.31,
p = 0.006). However, the most significant association in the
meta-analysis of common NINJ2 variants was an intronic SNP,
rs34166160 (MAF=0.012, HR=1.80, p = 0.0003), in the NINJ2
gene, which was in low LD (r2 = 0.02) with the sentinel GWAS
SNPs. When we repeated the analysis with adjustment for
rs12425791, the association was slightly attenuated (HR=1.66,
p = 0.002).
We annotated variants in LD (r2 .0.8) with the sentinel GWAS
SNPs for predicted functional impact on gene regulation using a
heuristic score metric implemented in RegulomeDB. We identified
2 variants, rs7297967 (MAF=0.45; RegulomeDB score = 1f) and
rs3782851 (MAF=0.06; RegulomeDB score = 3a), with predicted
functional impact on NINJ2 gene regulation. rs7297967 was
classified as likely to affect transcription factor binding and was
shown to be associated with NINJ2 gene expression levels [29],
while rs3782851 was less likely to affect transcription factor
binding. In the targeted sequencing sample, these 2 SNPs showed
nominal associations with incident ischemic stroke (p = 0.022 and
0.019, respectively) and modest effect sizes (HR=1.18 and 1.45,
respectively). As expected, these associations were no longer
significant after adjusting for rs12425791 (p = 0.42 and 0.34,
respectively).
We next examined the association of these 3 SNPs in an
independent sample of 6,066 participants from the Rotterdam
Study (mean follow-up: 12 years; 60% females; mean baseline age:
69 years), which included 353 incident atherothrombotic stroke
cases. rs3782851 was directly genotyped, while rs34166160 and
rs7297967 were imputed from the 1000 Genomes (Phase 1, V3)
CEU reference panel. Imputation quality for both SNPs was
excellent (Rsq.0.99). Estimated allele frequencies of rs7297967
and rs3782851 in the Rotterdam sample were similar to those in
the CHARGE sample (MAF=0.42 and 0.06, respectively), but
rs34166160 was much less frequent (MAF=0.006). rs7297967 was
nominally associated with incident ischemic stroke risk
(HR=1.18; p = 0.03) but rs3782851 and rs34166160 were not
(HR=1.18; p = 0.27 and HR=2.3; p = 0.20, respectively). How-
ever, power to detect effect sizes similar to those observed in
CHARGE in this Rotterdam sample was low to moderate for
these two SNPs (rs3782851, power = 0.68; rs34166160, pow-
er = 0.23).
Rare Variants Results
We performed a single burden test collapsing 278 variants of
MAF #1%, which also had a potential impact on protein function
or gene regulation. These included 268 variants with Regulo-
meDB score #3 and 10 coding variants within the NINJ2 exons.
Table 1. Characteristics of study participants.
ARIC CHS FHS
Sample size 1885 1131 970
Ischemic stroke, n 189 217 69
Atherothrombotic stroke, n 153 (71*) 167 (105*) 58 (53*)
Female, % 49% (39%#) 53.7% (54.8%#) 51.6% (51.2%#)
Mean baseline age, y 54.8 (58.5#) 72.5 (72.5#) 62.9 (75.4#)
Mean follow-up, y 18.2 (11.8#) 11.9 (7.4#) 8.6 (3.5#)
*Number of atherothrombotic stroke cases originally selected for resequencing.
#In ischemic stroke cases only.
doi:10.1371/journal.pone.0099798.t001
Table 2. Characteristics of variants in the NINJ2 targeted region.
Common Rare
(MAF $ 0.01) (MAF ,0.01)
Nonsynonymous 0 18
Synonymous 1 9
Intergenic 135 1,459
Intron 280 2,031
Upstream 5 48
39 Untranslated Region 3 7
59 Untranslated Region 1 4
Total 425 3,576
doi:10.1371/journal.pone.0099798.t002
NINJ2 Sequencing in Ischemic Stroke
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These variants, in aggregate, were modestly associated with lower
stroke incidence (HR=0.81; p= 0.026) (Figure 2).
Similar results were obtained in a secondary gene-based analysis
using a SKAT test. This test can be more powerful in situations
where multiple variants have different directions and/or magni-
tude of effects within the NINJ2 region. Jointly modeling the effects
of the 278 putatively-functional variants with MAF# 1%, we
observed a nominally significant association with incident ischemic
stroke (p = 0.03). This association was only slightly attenuated
when adjusting for rs12425791 (p= 0.04).
Discussion
We sequenced a 196-kb region around the NINJ2 gene in 3,986
participants from the CHARGE consortium and demonstrated
evidence of association between newly-characterized, low fre-
quency and rare sequence variants and ischemic stroke. In the
meta-analysis of variants with MAF$1%, we confirm an
association for the original GWAS SNPs in this smaller targeted
sample. Only one novel intronic NINJ2 variant, rs34166160,
showed an independent association with incident ischemic stroke.
In addition, burden test-based analysis of rare variants across the
NINJ2 region showed modest evidence that, in aggregate, rare
variants in this gene were also associated with ischemic stroke
incidence, but they appeared to mitigate stroke risk.
Although theoretical models have demonstrated that GWAS
findings can reflect the contributions of one or more uncommon or
rare variants, empirical data reporting such synthetic associations
remain sparse, especially for complex disorders.[30] The variant
Figure 1. Associations of common variants (MAF$1%) with incident ischemic stroke in the CHARGE Targeted Sequencing Study.
Association p-values are plotted against their genomic position.
doi:10.1371/journal.pone.0099798.g001
Figure 2. T1 test of association of rare variants with predicted
functional impact on protein function or gene regulation in the
3 cohorts. Shown are the hazard ratios (HR) and associated confidence
intervals for each cohort and the summary measure (diamond) from the
meta-analysis.
doi:10.1371/journal.pone.0099798.g002
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rs34166160, located in intron 1 of NINJ2, showed the strongest
association with incident ischemic stroke, which was slightly
attenuated after accounting for the effects of the GWAS sentinel
SNP rs12425791, suggesting possible allelic heterogeneity at this
locus. This association was however not replicated in an
independent sample, likely due to low power. Functional
annotation of rs34166160 using the ENCODE data indicated
that this variant is located in a region of open chromatin as
determined from DNaseI hypersensitivity and Formaldehyde-
Assisted Isolation of Regulatory Elements assays.[31] However,
there was minimal evidence that this variant disrupts transcription
factor binding [27], and no evidence of evolutionary constraint on
this variant (GERP score ,0). rs34166160 was associated with a
modest increase in ischemic stroke incidence (HR=1.80). The
effects of rs11833579 and rs12425791 on ischemic stroke risk were
even more modest, with HRs of 1.39 and 1.31, respectively, but
were similar to those reported in our genome-wide association
study.[5]
Rare variants in this region, in aggregate, also influenced stroke
incidence. In particular, cumulative burden of rare alleles that
affect NINJ2 gene regulation or function was associated with a
lower stroke incidence. These data highlight the complex
relationship between sequence variation in the NINJ2 gene and
ischemic stroke susceptibility.
Allelic heterogeneity at this locus, caused by multiple rare, low
frequency, and common variants with disparate effects on risk, was
suggested by analyses conditioning on the sentinel GWAS SNP
and showing only mild attenuation of effects. If confirmed, this
may help explain the conflicting findings of studies seeking to
replicate the original GWAS results. Ninjurin 2 is a broadly
expressed homophilic adhesion molecule. It is involved in
neuronal growth, plays a role in nerve regeneration, and may
affect how the brain tolerates cerebral ischemic insults. Thus,
variants that affect NINJ2 regulation or function may influence
stroke risk, either favorably or unfavorably.
Despite the large number of novel variants identified at the
NINJ2 locus, the causal set of variants underlying association with
stroke incidence remains unclear. Only few variants had a
potentially functional impact on the encoded gene product, and
none of them was common. Annotation of variants with predicted
functional impact on gene regulation using RegulomeDB identi-
fied 268 variants with MAF, 1%. Additional studies will be
needed to understand the mechanism(s) by which, in aggregate,
they influence stroke risk. Among the common variants, we
identified 2 novel variants, rs7297967 and rs3782851, with
predicted functional impact on NINJ2 gene regulation and that
were in LD with the sentinel GWAS SNPs. rs7297967 has
previously been associated with NINJ2 gene expression[29] and
maps to a region binding transcription factors and encompassing a
DNAseI footprint.[27] rs3782851 was also predicted to affect
transcription factor binding but with lower confidence due to a
more incomplete set of evidence. These 2 SNPs were only
nominally associated with stroke risk and had modest effect sizes.
Attempt at an independent replication of these variants’ associ-
ations in Rotterdam Study showed that rs7297967 was associated
with incident atherothrombotic stroke, with effects of similar
magnitude as that observed in the CHARGE sample.
Several limitations of our study must be acknowledged: First,
because of our limited sample size, we likely had little power to
detect functional variants with weak to moderate effects on
ischemic stroke risk and, thus, we may have failed to identify true
genetic associations. Second, we only considered single nucleotide
variants as a source of DNA sequence variation in our study and
did not investigate the role of copy number variants or other
structural variants. Third, the enrichment of our ischemic stroke
cases with the atherothrombotic stroke subtype did not distinguish
between individual subtypes such as those related to large and
small vessel disease. Because of the small sample size, we did not
perform analyses limited to specific ischemic subtypes. Possible
differences in the strength of association between NINJ2 variation
and specific ischemic stroke etiologies may further erode our
power to detect true effects. Fourth, although characterization of
the regions of transcription, transcription factor association,
chromatin structure and histone modification in the human
genome sequence is rapidly progressing[32], our ability to predict
function of sequence variants in this region remains imperfect and,
thus, further limited our ability to identify functional variants and,
hence, to fully capture their impact on stroke risk. Finally,
independent replication of findings was hampered by the limited
availability of sequence data on prospective cohort studies of
incident stroke. Replication is especially challenging for gene-
based associations and this limitation is magnified in the absence of
precise knowledge of functionally important regulatory gene
regions, which further erodes power.[33] Thus, definitive evidence
of an association of NINJ2 with risk for ischemic stroke cannot not
be firmly established.
Conclusion
In conclusion, resequencing of a 196-kb region around the
NINJ2 gene in 3,986 European-American participants of 3
prospective cohorts of the CHARGE consortium identified novel
associations of both common and rare variants with incident
ischemic stroke. While single common variants were associated
with increased ischemic stroke incidence, rare variants, in
aggregate, were associated with decreased stroke risk. These data
highlight the complexity of the genetic architecture underlying the
association of NINJ2 with ischemic stroke risk. Additional studies
that take into account the complex allelic architecture at the
NINJ2 locus will be needed to confirm and extend these novel
findings.
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